These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 683564

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH.
    Cancer; 1997 Apr 15; 79(8):1561-7. PubMed ID: 9118039
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [A case of IgD plasmacytoma with unusual neurological symptoms].
    Kubát R, Svehla F, Horácek J.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1977 Apr 15; 104(3):366-75. PubMed ID: 72024
    [Abstract] [Full Text] [Related]

  • 28. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
    Snigurowicz J, Kraj M, Rostkowska J, Maj S, Mariańska B, Mendek E, Roszkowski S, Kilian Z, Kołakowski L.
    Arch Immunol Ther Exp (Warsz); 1981 Apr 15; 29(2):145-53. PubMed ID: 7030265
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Gamma-D-paraproteinemia. Clinical case contribution based on 2 studies].
    Spengler GA, Bütler R, Pflugshaupt R, Lopez V, Barandun S.
    Schweiz Med Wochenschr; 1967 Feb 11; 97(6):170-8. PubMed ID: 4175061
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. High-dose melphalan followed by radical radiotherapy for the treatment of massive plasmacytoma of the chest wall.
    Das-Gupta EP, Sidra GM, Bessell EM, Lush RJ, Byrne JL, Russell NH.
    Bone Marrow Transplant; 2003 Oct 11; 32(8):759-61. PubMed ID: 14520418
    [Abstract] [Full Text] [Related]

  • 35. [12 years of Melphalan therapy in a case of Igu-lambda plasmacytoma and resulting therapeutic suggestions].
    Snigurowicz J, Rostkowska J, Slomkowski M, Sielczak M, Kraj M, Krzemińska-Lawkowiczowa I.
    Pol Arch Med Wewn; 1975 Oct 11; 54(4):369-77. PubMed ID: 810778
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Combination chemotherapy with CCNU, melphalan, methotrexate, and prednisone (CAMP) in 35 patients with advanced breast cancer.
    Hansen M, Palshof T, Osterlind K, Hansen HH, Mouridsen H.
    Cancer Treat Rep; 1977 Nov 11; 61(8):1603-5. PubMed ID: 922762
    [No Abstract] [Full Text] [Related]

  • 38. [Allergic reaction to melphalan].
    Bleichner F, Mende S.
    Onkologie; 1982 Aug 11; 5(4):195. PubMed ID: 6755332
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Therapy of paraproteinemic diseases].
    Fölsch E.
    Dtsch Med J; 1968 Aug 05; 19(15):517-22. PubMed ID: 4887941
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.